• Obesity Tx End-Around With Skye Bioscience's Punit Dhillon

  • Oct 21 2024
  • Length: 1 hr and 3 mins
  • Podcast

Obesity Tx End-Around With Skye Bioscience's Punit Dhillon

  • Summary

  • We love to hear from our listeners. Send us a message.

    While the trend toward CB1 inhibition for obesity took a small hit with the release of Novo Nordisk's small molecule oral cannabinoid receptor (CB1) inverse agonist monlunabant last month, Skye Bioscience Chairman and CEO Punit Dhillon is shaking it off. He's confident that his company's antibody-based approach to CB1 inhibition will make a moot point of the neuropsychiatric side effects that put a damper on Novo's data. On this episode of the Business of Biotech, we're digging into the uber-hot business of weight loss therapeutics and going deep with Dhillon on why Skye's blood/brain barrier-obeying antibody might turn the GLP-1 and small molecule approaches to obesity on their ears. Over the course of the conversation, we explore the ins-and-outs of the business of metabolic health, a space that's churning out one blockbuster after another.

    Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com.

    Subscribe to our monthly Business of Biotech newsletter.

    Get in touch with guest and topic suggestions: matt.pillar@lifescienceconnect.com

    Find Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/


    Show More Show Less
activate_Holiday_promo_in_buybox_DT_T2

What listeners say about Obesity Tx End-Around With Skye Bioscience's Punit Dhillon

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.